Rotigotine Mylan (rotigotine)
Generic
- Region
- 🇪🇺 EU
- Active substance
- rotigotine
- Company
- Mylan S.A.S
- Status
- Application withdrawn
- Therapeutic area
- Restless Legs Syndrome; Parkinson Disease
- Designations
- Generic
- Application
- EMEA/H/C/004286
- ATC
- N04BC09
- Official record
- www.ema.europa.eu
Indication
Treatment of idiopathic Restless Legs Syndrome and Parkinson's disease.
Regulatory milestones
No milestones recorded in the last year.
Same substance in other markets
- 🇪🇺 Neupro Authorised · UCB Pharma S.A.
- 🇪🇺 Leganto Withdrawn · UCB Pharma S.A.
Follow Rotigotine Mylan
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.